About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker LXRX · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Aug 26, 2026A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obs…
NCT06481891 · Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive H…
Sotagliflozin, Placebo
LXRX
Lexicon Pharmaceuticals
Phase 3Active, not recruiting500Jan 2027Registry ↗
Feb 13, 2026Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia
NCT04662281 · Postherpetic Neuralgia
Placebo, LX9211
LXRX
Lexicon Pharmaceuticals
Phase 2Completed79Nov 18, 2022Registry ↗
Oct 10, 2025A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
NCT06203002 · Diabetic Peripheral Neuropathic Pain
Placebo (blinded), LX9211 (blinded)
LXRX
Lexicon Pharmaceuticals
Phase 2Completed496Jan 14, 2025Registry ↗
Jun 25, 2025Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain
NCT04455633 · Diabetic Peripheral Neuropathy, Diabetes
LX9211, LX9211 Matching Placebo
LXRX
Lexicon Pharmaceuticals
Phase 2Completed319May 23, 2022Registry ↗
Oct 28, 2022Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsenin…
NCT03521934 · Heart Failure, Type 2 Diabetes Mellitus
Sotagliflozin, Placebo
LXRX
Lexicon Pharmaceuticals
Phase 3Terminated1,222Jun 5, 2020Registry ↗
Oct 28, 2022Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and…
NCT03315143 · Heart Failure, Type 2 Diabetes Mellitus
Sotagliflozin, Placebo
LXRX
Lexicon Pharmaceuticals
Phase 3Terminated10,584Jul 8, 2020Registry ↗
Jun 25, 2021Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2…
NCT03386344 · Type 2 Diabetes Mellitus
Sotagliflozin, Placebo
LXRX
Lexicon Pharmaceuticals
Phase 3Terminated376May 22, 2019Registry ↗
Jun 25, 2021Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes,…
NCT03242252 · Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 3
Placebo, Sotagliflozin
LXRX
Lexicon Pharmaceuticals
Phase 3Completed787Mar 25, 2019Registry ↗
Jun 25, 2021A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Partic…
NCT03242018 · Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 4
Placebo, Sotagliflozin
LXRX
Lexicon Pharmaceuticals
Phase 3Completed277May 16, 2019Registry ↗
Jun 21, 2021Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not C…
NCT02926937 · Type 2 Diabetes Mellitus
Sotagliflozin (SAR439954), Placebo
LXRX
Lexicon Pharmaceuticals
Phase 3Completed399Apr 22, 2019Registry ↗
May 11, 2021Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 D…
NCT03351478 · Type 2 Diabetes Mellitus
Sotagliflozin, Empagliflozin
LXRX
Lexicon Pharmaceuticals
Phase 3Completed770May 16, 2019Registry ↗
May 11, 2021Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Dia…
NCT03332771 · Type 2 Diabetes Mellitus
Sotagliflozin (SAR439954), Glimepiride
LXRX
Lexicon Pharmaceuticals
Phase 3Completed954Aug 6, 2019Registry ↗
May 11, 2021Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Partic…
NCT03292653 · Cardiac Failure Aggravated
Sotagliflozin, Placebo
LXRX
Lexicon Pharmaceuticals
Phase 2Terminated32Aug 17, 2019Registry ↗
May 11, 2021Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus W…
NCT03285594 · Type 2 Diabetes Mellitus
Sotagliflozin, Insulin glargine (HOE901)
LXRX
Lexicon Pharmaceuticals
Phase 3Completed571Sep 17, 2019Registry ↗
May 11, 2021Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus o…
NCT03066830 · Type 2 Diabetes Mellitus
Sotagliflozin (SAR439954), Placebo
LXRX
Lexicon Pharmaceuticals
Phase 3Completed507Apr 17, 2019Registry ↗
May 11, 2021Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Ba…
NCT02926950 · Type 2 Diabetes Mellitus
Sotagliflozin (SAR439954), Placebo
LXRX
Lexicon Pharmaceuticals
Phase 3Completed518Feb 26, 2019Registry ↗
Feb 12, 2020A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have I…
NCT02531035 · Type 1 Diabetes Mellitus (T1DM), High Level of Sugar (Gluco…
Sotagliflozin, Placebo
LXRX
Lexicon Pharmaceuticals
Phase 3Completed1,405Apr 2017Registry ↗
Feb 12, 2020Dose-ranging Study in Patients With Type 1 Diabetes Mellitus
NCT02459899 · Type 1 Diabetes Mellitus
Placebo, Sotagliflozin
LXRX
Lexicon Pharmaceuticals
Phase 2Completed141Aug 2016Registry ↗
Feb 12, 2020Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With…
NCT02421510 · Type 1 Diabetes Mellitus
Sotagliflozin, Sotagliflozin
LXRX
Lexicon Pharmaceuticals
Phase 3Completed782Nov 2016Registry ↗
Feb 12, 2020Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With…
NCT02384941 · Type 1 Diabetes Mellitus
Placebo, Sotagliflozin
LXRX
Lexicon Pharmaceuticals
Phase 3Completed793Sep 2016Registry ↗
Feb 12, 2020Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elev…
NCT02383940 · Type 1 Diabetes Mellitus
Sotagliflozin, Placebo
LXRX
Lexicon Pharmaceuticals
Phase 2Completed87Sep 2016Registry ↗
Feb 12, 2020Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabe…
NCT01742208 · Type 1 Diabetes Mellitus
Sotagliflozin, Placebo
LXRX
Lexicon Pharmaceuticals
Phase 2Completed36Jan 2014Registry ↗
Sep 17, 2019Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
NCT02026063 · Carcinoid Syndrome
Telotristat etiprate
LXRX
Lexicon Pharmaceuticals
Phase 3Completed124Sep 12, 2018Registry ↗
May 23, 2019A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute…
NCT01456052 · Ulcerative Colitis
Telotristat Etiprate, Placebo
LXRX
Lexicon Pharmaceuticals
Phase 2Completed59Sep 3, 2013Registry ↗
Mar 15, 2019Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome
NCT01104415 · Carcinoid Syndrome
Telotristat etiprate
LXRX
Lexicon Pharmaceuticals
Phase 2Completed15Feb 12, 2014Registry ↗
Feb 26, 2019Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function
NCT02647918 · Renal Impairment, Healthy
Sotagliflozin, Sotagliflozin
LXRX
Lexicon Pharmaceuticals
Phase 1Completed50Sep 2017Registry ↗
Dec 26, 2018Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Mana…
NCT00853047 · Carcinoid Syndrome
Telotristat etiprate, Octreotide LAR Depot
LXRX
Lexicon Pharmaceuticals
Phase 2Completed23Jun 2014Registry ↗
Oct 15, 2018Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairm…
NCT03423446 · Hepatic Impairment
Telotristat Ethyl
LXRX
Lexicon Pharmaceuticals
Phase 1Completed16Jun 15, 2018Registry ↗
Apr 25, 2018A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotrist…
NCT03302845 · Drug-drug Interaction
Omeprazole 40 MG, Famotidine 40 mg
LXRX
Lexicon Pharmaceuticals
Phase 1Completed32Oct 23, 2017Registry ↗
Feb 27, 2018TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndro…
NCT01677910 · Carcinoid Syndrome
Telotristat etiprate, Placebo-matching telotristat etiprate
LXRX
Lexicon Pharmaceuticals
Phase 3Completed135Mar 21, 2016Registry ↗
Feb 26, 2018Telotristat Etiprate for Carcinoid Syndrome Therapy
NCT02063659 · Carcinoid Syndrome
Telotristat etiprate, Placebo
LXRX
Lexicon Pharmaceuticals
Phase 3Completed76Mar 29, 2016Registry ↗
Nov 17, 2016PK Study of Sotagliflozin in Subjects With Hepatic Impairment
NCT02471274 · Hepatic Impairment, Healthy
sotagliflozin
LXRX
Lexicon Pharmaceuticals
Phase 1Completed32Dec 2015Registry ↗
Sep 7, 2016Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat…
NCT02195635 · Drug Interactions
Telotristat etiprate, Octreotide acetate
LXRX
Lexicon Pharmaceuticals
Phase 1Completed24Oct 2014Registry ↗
Mar 2, 2016Oral Contraceptive DDI Study
NCT02494609 · Healthy
sotagliflozin, oral contraceptive
LXRX
Lexicon Pharmaceuticals
Phase 1Unknown30Nov 2015Registry ↗
Oct 2, 2015Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets
NCT02373046 · Healthy
LX4211, LX4211
LXRX
Lexicon Pharmaceuticals
Phase 1Completed30Apr 2015Registry ↗
Sep 14, 2015Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-an…
NCT01528111 · Primary Open-angle Glaucoma, Ocular Hypertension
LX7101 (0.125%), LX7101 (0.25%)
LXRX
Lexicon Pharmaceuticals
Phase 1/2Completed63Jun 2012Registry ↗
Jul 9, 2015DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin
NCT02300363 · Healthy
Treatment A (rosuvastatin), Treatment B (LX4211)
LXRX
Lexicon Pharmaceuticals
Phase 1Completed24Nov 2014Registry ↗
Jul 9, 2015DDI Study With Multiple-dose LX4211 and Single Dose Digoxin
NCT02300350 · Healthy
Treatment A digoxin, Treatment B LX4211
LXRX
Lexicon Pharmaceuticals
Phase 1Completed24Dec 2014Registry ↗
Mar 23, 2015A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predo…
NCT01494233 · Irritable Bowel Syndrome
250 mg LX1033 tablets, Placebo tablet
LXRX
Lexicon Pharmaceuticals
Phase 2Completed373Sep 2013Registry ↗

39 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:14 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances